Friday, July 10, 2026

pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma

Celgene

Celgene clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Summit, USA HQ
2,104 Employees
EMA registrant Type
Company details
Status
Public
HQ
Summit, USA
Employees
2,104
Programs
45
Drugs
91
Patents
0
Intelligence · Clinical Programs

Celgene projects

9 ClinicalTrials.gov programs sponsored by Celgene.

Celgene has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CA059-001

    Celgene Europe Limited

    Acute Myeloid Leukemia and Myelodysplastic Syndromes

    phase 1 other active

    1 trial
  2. CA061-1001

    Celgene Europe Limited

    Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial
  3. CA061-1006

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial
  4. CA1190002

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 1 other active

    1 trial
  5. CC-486

    Celgene Europe Limited

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial
  6. CC-90010-GBM-002

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial
  7. CC-90010-ST-001

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial
  8. CC-90011-SCLC-001

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial
  9. pomalidomide

    Celgene Europe Limited

    Multiple Myeloma in Relapse

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Celgene have?

9 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.